Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis

Molecular Cancer Therapeutics

Volumn 7, Issue 5, 2008, Pages 1227-1236

  Chen, Shang Chiung ^a   Henry, Dale O ^a   Reczek, Peter R ^b   Wong, Michael K K ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Quintessence Biotechnology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; VITRONECTIN; DOXYCYCLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; EXPERIMENTAL NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENE INDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE ADENOCARCINOMA; TREATMENT OUTCOME; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VASCULAR ENDOTHELIUM; ANIMAL; CELL CULTURE; DRUG SCREENING; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROSTATE TUMOR; VASCULARIZATION;

ANIMALS; APOPTOSIS; DOXYCYCLINE; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; VITRONECTIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 49849091777     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0051     Document Type: Article

References (35)

1. DeClerck YA, Imren S, Montgomery AM, Mueller BM, Reisfeld RA, Laug WE. Proteases and protease inhibitors in tumor progression. Adv Exp Med Biol 1997;425:89-97.
2. Stephens RW, Brunner N, Janicke F, Schmitt M. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 1998;52:99-111.
3. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25-40.
4. Rakic JM, Maillard C, Jost M, et al. Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell Mol Life Sci 2003;60:463-73.
5. Conese M, Blasi F. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation. Biol Chem Hoppe-Seyler 1995;376:143-55.
6. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 1997;18:415-7.
7. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996;134:1563-71.
8. 3 binding to vitronectin. Nature 1996;383:441-3.
9. Loskutoff DJ, Curriden SA, Hu G, Deng G. Regulation of cell adhesion by PAI-1. APMIS 1999;107:54-61.
10. Allgayer H, Heiss MM, Schildberg FW. Prognostic factors in gastric cancer. Br J Surg 1997;84:1651-64.
11. Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg 2002;26:767-71.
12. Look MP, van Putten WLJ, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002;94:116-28.
13. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60:636-43.
14. Soff GA, Sanderowitz J, Gately S, et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 1995;96:2593-600.
15. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998;4:923-8.
16. Bajou K, Masson V, Gerard RD, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001;152:777-84.
17. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000;60:5839-47.
18. McMahon GA, Petitclerc E, Stefansson S, et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 2001;276:33964-8.
19. Stefansson S, Petitclerc E, Wong MKK, McMahon GA, Brooks PC, Lawrence DA. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 2001;276:8135-41.
20. Eitzman DT, Krauss JC, Shen T, Cui J, Ginsburg D. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 1996;87:4718-22.
21. Almholt K, Nielsen BS, Frandsen TL, Brunner N, Dano K, Johnsen M. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Oncogene 2003;22:4389-97.
22. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808-12.
23. Hawighorst T, Oura H, Streit M, et al. Thrombospondin-1 selectively inhibits early-stage carcinogenesis and angiogenesis but not tumor lymphangiogenesis and lymphatic metastasis in transgenic mice. Oncogene 2002;21:7945-56.
24. Giavazzi R, Giuliani R, Coltrini D, et al. Modulation of tumor angiogenesis by conditional expression of fibroblast growthfactor-2 affects early but not established tumors. Cancer Res 2001;61:309-17.
25. Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial growth factor is essential for initial but not continued in vivo growthof human breast carcinoma cells. Cancer Res 1997;57:3924-8.
26. Shockett P, Difilippantonio M, Hellman N, Schatz DG. A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. Proc Natl Acad Sci U S A 1995;92:6522-6.
27. Hebda PA, Whaley D, Kim HG, Wells A. Absence of inhibition of cutaneous wound healing in mice by oral doxycycline. Wound Repair Regen 2003;11:373-9.
28. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates withmetastasi s in invasive prostate carcinoma. Am J Pathol 1993;143:401-9.
29. sahi-Ozaki Y, Sato Y, Kanno T, Sata T, Katano H. Quantitative analysis of Kaposi sarcoma-associated herpesvirus (KSHV) in KSHV-associated diseases. J Infect Dis 2006;193:773-82.
30. Jankun J, Keck RW, Skrzypczak-Jankun E, Swiercz R. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res 1997;57:559-63.
31. Isogai C, Laug WE, Shimada H, et al. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Res 2001;61:5587-94.
32. Al Fakhri N, Chavakis T, Schmidt-Woll T, et al. Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininogen correlates with their anti-adhesive properties. Biol Chem 2003;384:423-35.
33. Li L, Wartchow CA, Danthi SN, et al. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys 2004;58:1215-27.
34. Hood JD, Bednarski M, Frausto R, et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002;296:2404-7.
35. Stefansson S, Su EJ, Ishigami S, et al. The contributions of integrin affinity and integrin-cytoskeletal engagement in endothelial and smooth muscle cell adhesion to vitronectin. J Biol Chem 2007;282:15679-89.